C₂N Diagnostics, LLC raised $15M in an investment from Eisai Inc. to scale up and provide broad access to its Precivity™ tests for Alzheimer’s disease pathology
C₂N Diagnostics, LLC raised $15M in an investment from Eisai Inc. to scale up and provide broad access to its Precivity™ tests for Alzheimer’s disease pathology
03/06/24, 12:09 PM
Location
st. louisMoney raised
$15 million
Industry
medical device
health diagnostics
biotechnology
health care
Investors
Eisai Inc.
C₂N Diagnostics, LLC has announced an investment of up to 15 million USD from Eisai Inc. The investment aims to scale up and provide broad access to its Precivity™ tests for patients with cognitive impairment, helping healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.